What coverage agrees on
Both reports agree that Dr. Reddy’s has entered India’s biosimilar immuno-oncology market with Nivorz, a biosimilar of Opdivo. They also agree the company is positioning the launch around treatment access.
India Pharma · India
Dr. Reddy’s launches biosimilar Nivorz in India
CATCH ME UP
Dr. Reddy’s has launched Nivorz, a biosimilar version of Opdivo, in India.
The company said the product was developed and manufactured in Hyderabad.
It was approved by the Drugs Controller General of India after trials involving 288 patients.
One report said the drug has approval across 12 cancer indications.
Why it mattersThe launch signals a new biosimilar immuno-oncology option that could expand treatment access and intensify competition in a high-value cancer drug market.
More context
Executives said the launch is intended to improve treatment access in oncology.
The market is estimated at nearly 3900 crore rupees in 2025.
AGREEMENT VS DISAGREEMENT
What lines up. What splits.
A quick read on shared facts, changing details, and different emphasis.
What is changing or disputed
One report says Nivorz is approved across 12 cancer indications, while the other only cites approval after trials involving 288 patients. Further reporting could clarify the full label and commercial rollout details.
HOW COVERAGE DIFFERS
Same story. Different emphasis.
Swipe through the perspectives. Labels describe coverage framing, not truth or quality.
Neutral2
The reporting says Dr. Reddy’s has launched Nivorz in India as a biosimilar of Opdivo. It states that the product was developed and manufactured in Hyderabad and approved by the Drugs Controller General of India after clinical trials. One report adds that the drug has approval across 12 cancer indications and comes in multiple vial strengths.
STORY TIMELINEHow the coverage developed
The latest eight dated reports, from earliest to newest.
How the coverage developed
FIRST-PARTY STATEMENTS
What the parties are saying
Attributed summaries from official party channels. These are claims, not independent reporting or fact checks.
GO DEEPER
Read the reporting
Scan each source take, then open the original article.
Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz
Quick source take
The Hindu reports that Dr Reddy Laboratories has entered the Indian biosimilar immuno-oncology market with the launch of Nivorz, which is a biosimilar of Bristol Myers Squibb Opdivo nivolumab. The company stated that the product was developed and manufactured in Hyderabad and approved by the Drugs Controller General of India following trials involving 288 patients. Executives highlighted that the launch aims to improve treatment access in an oncology market estimated at nearly 3900 crore rupees in 2025.
Dr Reddy’s forays into Indian biosimilar immuno-oncology market
Quick source take
The Times of India reports that pharmaceutical major Dr Reddy Laboratories has announced its entry into the Indian biosimilar immuno-oncology market with the rollout of Nivorz, a biosimilar version of Opdivo. According to the company, the drug has received approval across 12 cancer indications following evaluations in a multi-country clinical program. Executives noted that the product will be available in multiple vial strengths and is intended to address treatment access challenges in India.